4B Technologies was founded with its mission to focus on novel medicines for neurodegenerative diseases and neurological injuries. With deep insights in neurosciences and CNS drug discovery, we have developed a strategic framework to increase probability of success by tackling key challenges faced in CNS drug research and development, including targeting strategy, animal model development, basic-to-clinical translation, biomarkers, and clinical trial design. Through in-house drug discovery efforts as well as strategic alliance with academic and industrial partners, 4B Technologies has built and is advancing a pipeline of innovative medicines into the clinic to validate their therapeutic potentials. Our aspiration is to become a global leader in developing innovative medicines for neurological diseases. 4B Technologies was registered in Cayman and Hong Kong in 2017 and began its full operation in 2018 with preclinical R&D in Suzhou, and later clinical development in Beijing and Shanghai, China.